RBP4 and myeloid sarcoma: Subjects with incident MS had higher RBP4 levels at baseline than those without MS evident at baseline or follow-up (RBP4, 42.07 ± 14.37 μg/ml vs. 32.73 ± 9.65 μg/ml, P < 0.001 after adjustment for gender, age, puberty, physical activity and dietary intake; Fig. 1).